Menso J Nubé1, Sanne A E Peters2,3, Peter J Blankestijn4, Bernard Canaud5,6, Andrew Davenport7, Muriel P C Grooteman1, Gulay Asci8, Francesco Locatelli9, Francisco Maduell10, Marion Morena6,11, Ercan Ok8, Ferran Torres12,13, Michiel L Bots3. 1. Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands. 2. The George Institute for Global Health, University of Oxford, Oxford, UK. 3. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Department of Nephrology, University Medical Center Utrecht, Utrecht, The Netherlands. 5. Centre of Medical Excellence, Fresenius Medical Care Deutschland, Bad Homburg, Germany. 6. Dialysis Research and Training Institute, Montpellier, France. 7. University College London, Centre for Nephrology, Royal Free Hospital, London, UK. 8. Division of Nephrology, Ege University School of Medicine, Izmir, Turkey. 9. Department of Nephrology, Alessandro Manzoni Hospital, Lecco, Italy. 10. Nephrology Department, Hospital Clinic, Barcelona, Spain. 11. Biochemistry and Hormonology Department, CHU, PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France. 12. Biostatistics Unit, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. 13. Biostatistics and Data Management Platform, IDIBAPS, Hospital Clinic, Barcelona, Spain.
Abstract
Background: From an individual participant data (IPD) meta-analysis from four randomized controlled trials comparing haemodialysis (HD) with post-dilution online-haemodiafiltration (ol-HDF), previously it appeared that HDF decreases all-cause mortality by 14% (95% confidence interval 25; 1) and fatal cardiovascular disease (CVD) by 23% (39; 3). Significant differences were not found for fatal infections and sudden death. So far, it is unclear, however, whether the reduced mortality risk of HDF is only due to a decrease in CVD events and if so, which CVD in particular is prevented, if compared with HD. Methods: The IPD base was used for the present study. Hazard ratios and 95% confidence intervals for cause-specific mortality overall and in thirds of the convection volume were calculated using the Cox proportional hazard regression models. Annualized mortality and numbers needed to treat (NNT) were calculated as well. Results: Besides 554 patients dying from CVD, fatal infections and sudden death, 215 participants died from 'other causes', such as withdrawal from treatment and malignancies. In this group, the mortality risk was comparable between HD and ol-HDF patients, both overall and in thirds of the convection volume. Subdivision of CVD mortality in fatal cardiac, non-cardiac and unclassified CVD showed that ol-HDF was only associated with a lower risk of cardiac casualties [0.64 (0.61; 0.90)]. Annual mortality rates also suggest that the reduction in CVD death is mainly due to a decrease in cardiac fatalities, including both ischaemic heart disease and congestion. Overall, 32 and 75 patients, respectively, need to be treated by high-volume HDF (HV-HDF) to prevent one all-cause and one CVD death, respectively, per year. Conclusion: The beneficial effect of ol-HDF on all-cause and CVD mortality appears to be mainly due to a reduction in fatal cardiac events, including ischaemic heart disease as well as congestion. In HV-HDF, the NNT to prevent one CVD death is 75 per year.
Background: From an individual participant data (IPD) meta-analysis from four randomized controlled trials comparing haemodialysis (HD) with post-dilution online-haemodiafiltration (ol-HDF), previously it appeared that HDF decreases all-cause mortality by 14% (95% confidence interval 25; 1) and fatal cardiovascular disease (CVD) by 23% (39; 3). Significant differences were not found for fatal infections and sudden death. So far, it is unclear, however, whether the reduced mortality risk of HDF is only due to a decrease in CVD events and if so, which CVD in particular is prevented, if compared with HD. Methods: The IPD base was used for the present study. Hazard ratios and 95% confidence intervals for cause-specific mortality overall and in thirds of the convection volume were calculated using the Cox proportional hazard regression models. Annualized mortality and numbers needed to treat (NNT) were calculated as well. Results: Besides 554 patients dying from CVD, fatal infections and sudden death, 215 participants died from 'other causes', such as withdrawal from treatment and malignancies. In this group, the mortality risk was comparable between HD and ol-HDF patients, both overall and in thirds of the convection volume. Subdivision of CVD mortality in fatal cardiac, non-cardiac and unclassified CVD showed that ol-HDF was only associated with a lower risk of cardiac casualties [0.64 (0.61; 0.90)]. Annual mortality rates also suggest that the reduction in CVD death is mainly due to a decrease in cardiac fatalities, including both ischaemic heart disease and congestion. Overall, 32 and 75 patients, respectively, need to be treated by high-volume HDF (HV-HDF) to prevent one all-cause and one CVD death, respectively, per year. Conclusion: The beneficial effect of ol-HDF on all-cause and CVD mortality appears to be mainly due to a reduction in fatal cardiac events, including ischaemic heart disease as well as congestion. In HV-HDF, the NNT to prevent one CVD death is 75 per year.
Authors: Damien Ashby; Natalie Borman; James Burton; Richard Corbett; Andrew Davenport; Ken Farrington; Katey Flowers; James Fotheringham; R N Andrea Fox; Gail Franklin; Claire Gardiner; R N Martin Gerrish; Sharlene Greenwood; Daljit Hothi; Abdul Khares; Pelagia Koufaki; Jeremy Levy; Elizabeth Lindley; Jamie Macdonald; Bruno Mafrici; Andrew Mooney; James Tattersall; Kay Tyerman; Enric Villar; Martin Wilkie Journal: BMC Nephrol Date: 2019-10-17 Impact factor: 2.388
Authors: Francesco Locatelli; Angelo Karaboyas; Ronald L Pisoni; Bruce M Robinson; Joan Fort; Raymond Vanholder; Hugh C Rayner; Werner Kleophas; Stefan H Jacobson; Christian Combe; Friedrich K Port; Francesca Tentori Journal: Nephrol Dial Transplant Date: 2018-04-01 Impact factor: 5.992
Authors: Paul A Rootjes; Camiel L M de Roij van Zuijdewijn; Muriel P C Grooteman; Michiel L Bots; Bernard Canaud; Peter J Blankestijn; Frans J van Ittersum; Francisco Maduell; Marion Morena; Sanne A E Peters; Andrew Davenport; Robin W M Vernooij; Menso J Nubé Journal: Kidney Int Rep Date: 2020-01-31
Authors: Peter J Blankestijn; Kathrin I Fischer; Claudia Barth; Krister Cromm; Bernard Canaud; Andrew Davenport; Diederick E Grobbee; Jörgen Hegbrant; Kit C Roes; Matthias Rose; Giovanni Fm Strippoli; Robin Wm Vernooij; Mark Woodward; G Ardine de Wit; Michiel L Bots Journal: BMJ Open Date: 2020-02-05 Impact factor: 2.692
Authors: Elena Rodríguez-Sánchez; José Alberto Navarro-García; Jennifer Aceves-Ripoll; Judith Abarca-Zabalía; Andrea Susmozas-Sánchez; Teresa Bada-Bosch; Eduardo Hernández; Evangelina Mérida-Herrero; Amado Andrés; Manuel Praga; Mario Fernández-Ruiz; José María Aguado; Julián Segura; Luis Miguel Ruilope; Gema Ruiz-Hurtado Journal: Biomolecules Date: 2020-03-26